Home
Login
Help
Search this site:
Registered Trials
By recruitment status
By sponsor
By registration date
Advanced search for trials
Registration process
To register a trial
Sponsor registration form
RPCEC trial registration Data Set
To update a registered trial
To disclosure the results of registered trial
Home
|
CIGB500 in healthy volunteers
View current
Revisions
List all revisions
View
Compare to current
9 April 2013 - 3:06pm
by Webmaster
16 January 2017 - 10:49am
by lazara
Changes to
First name
-
Angel
Abreu Cruz
,
MD
Marbelia
Iglesias González
,
MD
Anselmo
Abdo Cuza, MD
+
Angel,
Marbelia,
Anselmo
.
Changes to
Last name
-
Not entered
+
Abreu Cruz, Iglesias González, Abdo Cuza
Changes to
Health condition(s) code
-
+
Healthy Volunteers
Changes to
Medical Specialty
-
+
Specialist of second degree in cardiology
Changes to
Affiliation
-
Not entered
+
Surgical Medical Research Center
Changes to
Postal address
-
Not entered
+
216 and 11-B, Siboney, Playa
Changes to
Intervention code
-
+
Peptides
+
Administration, Intravenous
+
Single Dose
Changes to
Intervention keyword
-
+
CIGB500
Changes to
City
-
Not entered
+
Havana
Changes to
Country
-
Not entered
+
Cuba
Changes to
Zip Code
-
Not entered
+
11300
Changes to
Specialty
-
+
2nd Degree Specialist in Hygiene and Epidemiology
Changes to
City
-
Havana
City
+
Havana
Changes to
Specialty
-
+
2nd Degree Specialist in Hygiene and Epidemiology
Changes to
City
-
Havana
City
+
Havana
Changes to
Record Verification Date
-
2008-
01
-09 19:00
+
2017/
01
/16
Changes to
Next update date
-
+
2018/01/16
Revision of 16 January 2017 - 10:49am:
CIGB500 in healthy volunteers
General information
Section to complete general information about the trial: scientific and public title, protocol identifiers, sponsors and Source(s) of Monetary or Material Support.
Scientific title:
Administration of CIGB500 in healthy volunteers. Phase I study on scaling up dosages.
Secondary indentifying numbers:
IG/CIGB500I/SG/0601
Issuing authority of the secondary identifying numbers:
Center for Genetic Engineering and Biotechnology (CIGB), Havana City
Primary sponsor:
Center for Genetic Engineering and Biotechnology (CIGB), Havana City
Secondary sponsor:
Not applicable
Source(s) of monetary or material support:
Heber Biotec S.A.
Authorization for beginning
Section to complete information about the regulatory approval of clinical trial: regulatory agency name, approval date and reference number in the agency.
Regulatory instance to authorize the initiation of the study:
Center for State Control of the Quality of Drugs(CECMED)
Authorization date :
28/08/2007
Reference number:
1657/06.033.07B
Principal investigator
Section to complete information about Email address, telephone number and postal address of the Principal Investigator.
First name:
Angel, Marbelia, Anselmo .
Last name:
Abreu Cruz, Iglesias González, Abdo Cuza
Medical Specialty :
Specialist of second degree in cardiology
Affiliation:
Surgical Medical Research Center
Postal address:
216 and 11-B, Siboney, Playa
City:
Havana
Country:
Cuba
Zip Code:
11300
Telephone:
+53-78501000
Email address:
email@not.entered
Clinical sites to participate
Section to complete the data related to the clinical sites involved in the trial: site and responsible investigator for every site.
Countries of recruitment:
Cuba
Clinical sites:
Not applicable
Research ethics committees:
Medical – Surgical Research Center, Havana, July 18, 2007.
Recruitment status
Section to complete information about the recruitment status and the date of first enrolment subject
Recruitment status:
Complete
Date of first enrollment:
11/12/2007
Health condition and Intervention
Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).
Health condition(s) or Problem(s) studied:
Healthy volunteers
Health condition(s) code:
Healthy Volunteers
Intervention(s):
Administration at a single dose through the endovenous route at 6 scale levels of the doses: 1, 10, 50, 100, 200 and 400 µg/kg.
Intervention code:
Peptides
Administration, Intravenous
Single Dose
Intervention keyword:
CIGB500
Outcomes and Timepoint
Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.
Primary outcome(s):
Clinical Adverse events. The type, duration, intensity, severity, causal relation and therapeutic conduct. For this, the subject has been evaluate through their interrogation and physical examination, at least at the start, at 24 hours, 48 hours, 72 hours and at 10 days after applying the product, but also at any moment in which any event was observed. Vital signs. Blood pressure, heart rate, respiratory rate and axillar temperature. Although these variables also form part of the evaluations of the clinical adverse events, a separate section has been includ since they were strictly followed during and after the application of the product. The records of the vital signs were carried out at the start after the administration of the product at 30 minutes and at 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 hours. Electrocardiogram (ECG). An electrogradiograph monitoring has been perform during the first 24 hours after the administration of the product using the standard calibration of 10mm=1mV and the speed of the paper at 25 mm/second. The first evaluation was at the start in an interval of 30 minutes before the administration of the product and after applying it the records were taken at the following times: 30 minutes and at 1, 2, 4, 6, 8, 10, 12 and 24 hours. Laboratory tests. The samples for the determinations have been collect while fasting as part of the pre-entrance examination, at 72 hours and at 10 days.
Key secondary outcomes:
Pharmacokinetics of the CIGB500 (only the doses of 100 _g/kg, 200 _g/kg and 400 _g/kg): The blood samples have been extract before the administration and after concluding the administration), 10, 20 and 30 minutes; and at 1, 2, 4, 6, 8, 10, 12, 24, 48 and 72 hours. Pharmacodynamic effects: Blood samples have been take immediately before administering the product and at 10, 20 and 30 minutes, as well as after one hour, 2 and 24 hours. Echocardiograms Studies: On the pre-entrance examinations, at 72 hours and 10 days before administering the product.
Selection criterias
Section to complete information about the inclusion and exclusion criteria for participant selection, including age and gender.
Gender:
Male
Minimum age:
18 years
Maximum age:
35 years
Inclusion criteria:
Male individuals of 18 to 35 years of age. Absence of important clinical signs during the interrogation and in the physical examination. Normal Electrocardiogram. Analysis of hematology, plasmatic biochemistry and urine within the normal limits. Normal body weight according to height. Willingness of the individual shown by signing the written consent.
Exclusion criteria:
History of endocrine-metabolic alterations. History of significant acute diseases in the last 30 days. History of chronic diseases (cardiovascular, respiratory, neurological, renal, respiratory, gastrointestinal, liver or hematological diseases). Administration of a pharmaceutical under study within 45 of having entered the study. Use of some medicine within 15 days before having entered the study. Donation or loss of blood greater than 400 mL within 12 weeks before entering the study. Severe adverse reactions or hypersensitivity to a drug. History of alcoholism or alcohol consumption within 24 before the administration of the drug. Consuming more than 10 cigarettes a day.
Type of population:
Adults
Type of participant:
Healthy volunteers
Study design
Section to complete information about the characteristics of the study design.
Type study:
Interventional
Purpose:
Other
Allocation:
Non-randomized controlled trial
Masking:
Open
Control group:
Uncontrolled
Study design:
Other
Other design:
Dose escalations
Phase:
1
Target sample size:
18
Contact for public queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status
First Name:
Francisco
Last Name:
Hernández-Bernal
Specialty:
2nd Degree Specialist in Hygiene and Epidemiology
Affiliation:
Center for Genetic Engineering and Biotechnology.
Postal Address:
Ave. 31 e/ 158 y 190 Cubanacán, Playa
City:
Havana
Country:
Cuba
Zip Code:
6162
Telephone:
(53-7)-2085887
Email :
hernandez.bernal@cigb.edu.cu
Contact for scientific queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to scientific queries.
First Name:
Francisco
Last Name:
Hernández-Bernal
Specialty:
2nd Degree Specialist in Hygiene and Epidemiology
Affiliation:
Center for Genetic Engineering and Biotechnology.
Postal Address:
Ave. 31 e/ 158 y 190 Cubanacán, Playa
City:
Havana
Country:
Cuba
Zip Code:
6162
Telephone:
(53-7)-2085887
Email :
hernandez.bernal@cigb.edu.cu
Registration and Update
Section to complete information about the name of Primary Registry, date of registration and the unique ID number assigned by the registry (RPCEC).
Primary registry:
RPCEC
Unique ID number:
RPCEC00000017
Date of Registration in Primary Registry:
2010-12-20
Record Verification Date:
2017/01/16
Next update date:
2018/01/16
Link to the spanish version:
Click here
About the RPCEC
Structure and governance
Policy
Publications
Awards
Communications
News
Useful resources
Fundamentals of the registry
References of clinical trials
Cuban regulations
Other registries
International Clinical Trials Registry Platform